Roche Hands Over US$1.7 B for Ignyta Buyout
By Natasha Piper
Pharma Deals Review: Vol 2018 Issue 1 (Table of Contents)
Published: 13 Jan-2018
DOI: 10.3833/pdr.v2018.i1.2295 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Roche has agreed to acquire cancer drug developer Ignyta for US$27 per share, equating to a total transaction value of US$1...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS